Novel oral anticoagulants: What dermatologists need to know - 15/02/15
![](/templates/common/images/mail.png)
Abstract |
The development of novel oral anticoagulants provides clinicians and patients a welcome alternative to the challenges of warfarin therapy. Dermatologists must be aware of the potential impact of novel oral anticoagulants on their surgical and medical practice. This review provides a concise summary of the novel oral anticoagulants for dermatologists with particular emphasis on: (1) the pharmacokinetic properties of these drugs and how they differ from warfarin, (2) suggested management during cutaneous surgery, (3) adverse drug interactions with commonly prescribed medications in dermatology, and (4) potential use within dermatology for treatment of disorders of cutaneous thrombosis.
Le texte complet de cet article est disponible en PDF.Key words : anticoagulation, apixaban, cutaneous surgery, dabigatran, novel drugs, rivaroxaban, warfarin
Abbreviations used : CYP3A4, NOAC, P-gp
Plan
Funding sources: None. |
|
Conflicts of interest: None declared. |
Vol 72 - N° 3
P. 535-540 - mars 2015 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?